TY - JOUR
T1 - Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders
T2 - Results of a phase II North Central Cancer Treatment Group trial
AU - Witzig, Thomas E.
AU - Letendre, Louis
AU - Gerstner, James
AU - Schroeder, Georgene
AU - Mailliard, James A.
AU - Colon-Otero, Gerardo
AU - Marschke, Robert F.
AU - Windschitl, Harold E.
PY - 1995/8
Y1 - 1995/8
N2 - Purpose: Malignant cells from non-Hodgkin's lymphomas (NHL) have been shown to express the somatostatin receptor on their cell surface and most NHL are visible on somatostatin radioscintigraphy scans. This provided the rationale to conduct a phase II trial of a somatostatin analog in patients with B- and T-cell lymphoproliferative disorders. Patients and Methods: Sixty-one patients with measurable or assessable lymphoproliferative disorders (31 stage III or IV low-grade NHL; 21 chronic lymphocytic leukemia [CLL]; and nine cutaneous T-cell NHL [CTCL]) were enrolled. Patients were treated with somatostatin 150 μg subcutaneously (SQ) every 8 hours for 1 month. Patients with stable or responding disease received 2 additional months of therapy; those who responded after 3 months were treated for an additional ≥ 3 months. Results: Sixty patients were assessable for toxicity and 56 for response. There were no complete remissions. In the low-grade NHL group, 36% (10 of 28 patients; 95% confidence interval [CI], 19% to 56%) had a partial remission. Forty-four percent (four of nine; 95% CI, 14% to 79%) of patients with CTCL had a partial response. No patients with CLL had a partial remission. Among 45 patients with stable disease or a partial remission, the mean time to progression (TTP) was 10.9 months (median, 6.2; range, 1.6 to 48.5). The drug was well tolerated, with the most common side effects being diarrhea and hyperglycemia. Conclusion: Somatostatin at a dose of 150 μg every 8 hours is well tolerated and has activity in low-grade NHL.
AB - Purpose: Malignant cells from non-Hodgkin's lymphomas (NHL) have been shown to express the somatostatin receptor on their cell surface and most NHL are visible on somatostatin radioscintigraphy scans. This provided the rationale to conduct a phase II trial of a somatostatin analog in patients with B- and T-cell lymphoproliferative disorders. Patients and Methods: Sixty-one patients with measurable or assessable lymphoproliferative disorders (31 stage III or IV low-grade NHL; 21 chronic lymphocytic leukemia [CLL]; and nine cutaneous T-cell NHL [CTCL]) were enrolled. Patients were treated with somatostatin 150 μg subcutaneously (SQ) every 8 hours for 1 month. Patients with stable or responding disease received 2 additional months of therapy; those who responded after 3 months were treated for an additional ≥ 3 months. Results: Sixty patients were assessable for toxicity and 56 for response. There were no complete remissions. In the low-grade NHL group, 36% (10 of 28 patients; 95% confidence interval [CI], 19% to 56%) had a partial remission. Forty-four percent (four of nine; 95% CI, 14% to 79%) of patients with CTCL had a partial response. No patients with CLL had a partial remission. Among 45 patients with stable disease or a partial remission, the mean time to progression (TTP) was 10.9 months (median, 6.2; range, 1.6 to 48.5). The drug was well tolerated, with the most common side effects being diarrhea and hyperglycemia. Conclusion: Somatostatin at a dose of 150 μg every 8 hours is well tolerated and has activity in low-grade NHL.
UR - http://www.scopus.com/inward/record.url?scp=0029166909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029166909&partnerID=8YFLogxK
U2 - 10.1200/JCO.1995.13.8.2012
DO - 10.1200/JCO.1995.13.8.2012
M3 - Article
C2 - 7636542
AN - SCOPUS:0029166909
SN - 0732-183X
VL - 13
SP - 2012
EP - 2015
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -